| Literature DB >> 34550383 |
Jie Yang1,2, John W Lian2,3, Yen-Po Harvey Chin2,4, Liqin Wang1,2, Anna Lian5, George F Murphy2,3, Li Zhou1,2.
Abstract
Importance: Although tumor-infiltrating lymphocytes (TILs) are an important histopathologic characteristic reflecting host immune response in patients with melanoma, their prognostic value remains controversial. Because manual review of medical records is labor intensive, a survival analysis using a large patient cohort with comprehensive clinical and histopathologic characteristics is lacking. Objective: To assess the prognostic significance of TILs among patients with cutaneous melanoma using a large cohort established through natural language processing (NLP) algorithms. Design, Setting, and Participants: This retrospective cohort study analyzed the medical records of 14 436 patients with cutaneous melanoma at Brigham and Women's Hospital between June 1, 2004, and December 31, 2019. Patients were followed up to death or censored at their last clinical visit. Main Outcome and Measures: The primary outcome was overall survival (OS). Survival analysis was conducted using Kaplan-Meier curves, the log-rank test, and Cox proportional hazards regression analysis.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34550383 PMCID: PMC8459191 DOI: 10.1001/jamanetworkopen.2021.26337
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure 1. Patient Cohort Selection Process
NLP indicates natural language processing; TILs, tumor-infiltrating lymphocytes.
Demographic and Pathologic Characteristics of the Study Population and Their Differences in 3 TIL Grades
| Characteristic | No. (%) | ||||
|---|---|---|---|---|---|
| Total (N = 2624) | TIL grade | ||||
| Absent (n = 434) | Nonbrisk (n = 1916) | Brisk (n = 274) | |||
| Age, median (IQR), y | 61 (50-72) | 63 (52-72) | 61 (50-72) | 58 (47-67) | .002 |
| <50 | 642 (24.5) | 90 (20.7) | 472 (24.6) | 80 (29.2) | .009 |
| 50-69 | 1258 (47.9) | 219 (50.5) | 899 (46.9) | 140 (51.1) | |
| ≥70 | 724 (27.6) | 125 (28.8) | 545 (28.4) | 54 (19.7) | |
| Sex | |||||
| Female | 1162 (44.3) | 200 (46.1) | 829 (43.3) | 133 (48.5) | .18 |
| Male | 1462 (55.7) | 234 (53.9) | 1087 (56.7) | 141 (51.5) | |
| Breslow thickness, median (IQR), mm | 1.2 (0.7-2.5) | 1.3 (0.7-2.9) | 1.2 (0.7-2.6) | 0.9 (0.6-1.5) | <.001 |
| ≤1 (T1) | 1082 (41.2) | 165 (38.0) | 759 (39.6) | 158 (57.7) | <.001 |
| 1.01 to 2 (T2) | 630 (24.0) | 103 (23.7) | 461 (24.1) | 66 (24.1) | |
| 2.01 to 4 (T3) | 423 (16.1) | 67 (15.4) | 325 (17.0) | 31 (11.3) | |
| >4 (T4) | 403 (15.4) | 83 (19.1) | 303 (15.8) | 17 (6.2) | |
| Unknown | 86 (3.3) | 16 (3.7) | 68 (3.5) | 2 (0.7) | |
| Mitotic rate, median (IQR) | 2 (1-6) | 2 (1-6) | 2 (1-6) | 1 (0-3) | <.001 |
| Ulceration | |||||
| Absent | 2040 (77.7) | 352 (81.1) | 1448 (75.6) | 240 (87.6) | <.001 |
| Present | 536 (20.4) | 76 (17.5) | 427 (22.3) | 33 (12.0) | |
| Unknown | 48 (1.8) | 6 (1.4) | 41 (2.1) | 1 (0.4) | |
| Histological regression | |||||
| Absent | 1969 (75.0) | 381 (87.8) | 1439 (75.1) | 149 (54.4) | <.001 |
| Present | 628 (23.9) | 49 (11.3) | 457 (23.9) | 122 (44.5) | |
| Unknown | 27 (1.0) | 4 (0.9) | 20 (1.0) | 3 (1.1) | |
| Microscopic satellites | |||||
| Absent | 1387 (52.9) | 225 (51.8) | 1003 (52.3) | 159 (58.0) | .007 |
| Present | 65 (2.5) | 15 (3.5) | 50 (2.6) | 0 (0.0) | |
| Unknown | 1172 (44.7) | 194 (44.7) | 863 (45.0) | 115 (42.0) | |
| Vascular/lymphatic invasion | |||||
| Absent | 177 (6.7) | 56 (12.9) | 112 (5.8) | 9 (3.3) | <.001 |
| Present | 1468 (55.9) | 250 (57.6) | 1092 (57.0) | 126 (46.0) | |
| Unknown | 979 (37.3) | 128 (29.5) | 712 (37.2) | 139 (50.7) | |
Abbreviations: IQR, interquartile range; TIL, tumor-infiltrating lymphocyte.
The Kruskal-Wallis rank test was used for continuous variables, the χ2 test was used for sex and vascular or lymphatic invasion, and the Fisher exact test was used for the characteristics with fewer than 5 patients (ie, Breslow thickness category, ulceration, histologic regression, and microscopic satellites).
Based on American Joint Committee on Cancer staging: T1, Breslow thickness 1.0 mm or less; T2, Breslow thickness 1.01 to 2.0 mm; T3, Breslow thickness 2.01 to 4.0 mm; and T4, Breslow thickness greater than 4.0 mm.
Figure 2. Kaplan-Meier Survival Curve for All Patients
TILs indicate tumor-infiltrating lymphocytes.
Risk Factors Associated With Survival Among Patients With Vertical Growth Phase Melanoma
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | Adjusted HR (95% CI) | |||
| Age, y | ||||
| <50 | 1 [Reference] | NA | 1 [Reference] | NA |
| 50-69 | 1.94 (1.45-2.60) | <.001 | 1.65 (1.22-2.24) | <.001 |
| ≥70 | 4.29 (3.21-5.75) | <.001 | 3.37 (2.48-4.58) | <.001 |
| Sex | ||||
| Female | 1 [Reference] | NA | 1 [Reference] | NA |
| Male | 1.77 (1.47-2.13) | <.001 | 1.50 (1.23-1.82) | <.001 |
| TILs | ||||
| Absent | 1 [Reference] | NA | 1 [Reference] | NA |
| Brisk | 0.51 (0.34-0.75) | <.001 | 0.63 (0.42-0.95) | .03 |
| Nonbrisk | 0.97 (0.77-1.22) | .79 | 0.87 (0.68-1.11) | .25 |
| Breslow thickness, mm | 1.11 (1.09-1.13) | <.001 | 1.05 (1.03-1.08) | <.001 |
| ≤1 (T1) | 1 [Reference] | NA | NA | NA |
| 1.01 to 2 (T2) | 1.81 (1.38-2.38) | <.001 | NA | NA |
| 2.01 to 4 (T3) | 3.53 (2.73-4.57) | <.001 | NA | NA |
| >4 (T4) | 5.54 (4.33-7.10) | <.001 | NA | NA |
| Unknown | 2.51 (1.59-3.98) | <.001 | NA | NA |
| Mitotic rate | 1.03 (1.03-1.04) | <.001 | 1.02 (1.01-1.03) | <.001 |
| Ulceration | ||||
| Absent | 1 [Reference] | NA | 1 [Reference] | NA |
| Present | 3.34 (2.78-4.01) | <.001 | 2.14 (1.70-2.70) | <.001 |
| Unknown | 2.22 (1.22-4.06) | .009 | 2.09 (1.07-4.09) | .03 |
| Histologic regression | ||||
| Absent | 1 [Reference] | NA | NA | NA |
| Present | 0.97 (0.79-1.18) | .75 | NA | NA |
| Unknown | 1.02 (0.42-2.47) | .96 | NA | NA |
| Microscopic satellites | ||||
| Absent | 1 [Reference] | NA | 1 [Reference] | NA |
| Present | 3.48 (2.37-5.12) | <.001 | 1.88 (1.23-2.87) | .004 |
| Unknown | 0.82 (0.68-0.99) | .04 | 0.86 (0.71-1.05) | .14 |
| Vascular or lymphatic invasion | ||||
| Absent | 1 [Reference] | NA | 1 [Reference] | NA |
| Present | 1.77 (1.19-2.65) | .005 | 1.58 (1.05-2.38) | .03 |
| Unknown | 1.41 (0.93-2.12) | .10 | 1.59 (1.05-2.42) | .03 |
Abbreviations: HR, hazard ratio; TILs, tumor-infiltrating lymphocytes.
Of the 2624 patients, 86 patients were excluded owing to unclear invasion depths, and 2538 patients were included in the multivariable analysis.
Based on American Joint Committee on Cancer staging: T1, Breslow thickness 1.0 mm or less; T2, Breslow thickness 1.01 to 2.0 mm; T3, Breslow thickness 2.01 to 4.0 mm; and T4, Breslow thickness greater than 4.0 mm.